Authored by James Sheppard
At the beginning of 2013 Liftstream profiled 13 life science leaders we believed were going to make an impact over the course of the year. Below we outline how Dr John Martin performed for Gilead in 2013.
2013 Liftstream Analysis: Gilead Sciences had a very active 2012 launching a number of drugs. The Pharmasset acquisition hangs over the company and Martin will need to continue to show investors this deal was worth its hefty price. Gilead is emerging as a leader in Hepatitis C and has recently expanded into the oncology field. 2013 will produce a number of key clinical results for Gilead, namely Phase II &III trials of HCV drug Sofosbuvir. Gilead has made no secret of their ambition to expand into oncology and haematology and Martin is expected to continue this diversification.
• Ensure Gilead remains on track with clinical programs
• Effectively manage the integration and value opportunities of Pharmasset and YM Bioscience
• Consolidate position in HIV and anti-infectives.
2014 Liftstream Verdict: A hugely successful year for Gilead cemented their place as one of the hottest companies in the sector. Hepatitis C has been a major focus for the industry in 2013 and Gilead have be right at the centre of that innovation Sovaldi, has achieved both FDA and EMA approval for Hep C and analysts project one of the biggest drug launches of all time, with some $4.5bn in sales in 2014 alone. Away from Hep C, Gilead had more positive news in its impressive HIV franchise with successes at the FDA and EMA and their haematology franchise continues to show great promise with potential new therapies in Indolent non-Hodgkin’s Lymphoma, Chronic Lymphocytic Leukemia and Myelofibrosis. A hugely successful year for John Martin and Gilead saw the share price rising over 100%. The company saw the departure of long term employee Kevin Young, EVP Commercial Operations who retires. The company will face a significant task to launch Sovaldi on a global basis and strong leadership of the commercial function will be an imperative. 2013 was an outstanding year for the company and with so many late phase programmes, it looks like Gilead has a good trajectory.
To see how the other leaders profiled in Liftstream’s 13 for 2013 performed please click here. Liftstream would very much like to hear your thoughts on how you believe these life science leaders performed in 2013. Please leave your comments below, email firstname.lastname@example.org or tweet @liftstream #LSL13for13
Liftstream is an executive search and interim management recruitment company working exclusively within the global life sciences sector.